Richter Eyes More Drug Licensing Deals to Sidestep Trump Tariffs

Gedeon Richter, Hungary’s biggest drugmaker, aims to clinch more deals like its partnership with AbbVie Inc.to expand in the US without being weighed down by import tariffs imposedby President Donald Trump.

Read more: Richter Grows in Line With Guidance as Key Vraylar Drug Delivers

Richter generated $622 million last year in royalties from its licensing deal with Abbvie, which markets its blockbuster anti-psychotic drug as Vraylar in the US. That income stream won’t be subject to tariffs and is a model Richter wants to pursue with more local US partners in key areas such as women’s health ...